$TJX

Jim Cramer Notes He Is Buying The Pullback In TJX

Jim Cramer recommended buying The TJX Companies (TJX) during its recent pullback, citing its low valuation. TJX reported Q2 2027 revenue of $15.2B, beating estimates, with 4% comparable sales growth. However, Marmaxx saw only 1% growth, and margins faced pressure from rising costs. The stock is near $127, down from a 52-week high of $170. Hedge fund ownership and short interest are noted.

Original reporting
Published Sep 21, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 7:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jim Cramer Notes He Is Buying The Pullback In TJX — source image
Decision brief

The 30-second read

$TJXNeutralLow
01

Why it matters

The piece reiterates known earnings results; no new material information.

02

Market read

Recap of TJX Q2 earnings and a host’s buying comment; limited trading relevance.

03

What to watch

Potential macro‑headwinds from consumer spending slowdown are not addressed.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

Jim Cramer discusses buying TJX on the dip after a recent earnings beat and guidance raise.

Company-level read

Ticker impact

$TJXNeutralMedium confidence
Context

Article recaps TJX Q2 results and Cramer's buy recommendation after the stock fell from $170 to $127.

Expected impact

Limited short‑term impact; any move would depend on trader sentiment rather than fresh fundamentals.

Evidence & confidence

The article repeats previously released earnings numbers and guidance, offering no novel catalyst.

Market effects

Off‑price retail sector remains unchanged; no new sector‑wide driver.

U.S. retail market perception unchanged.

Minimal; article is U.S.‑focused.

Counterpoint

Without fresh data, the suggested entry may be premature; price could stay flat.

Key entities

  • The TJX Companies, Inc.

    Off‑price retailer discussed in the article.

  • Jim Cramer

    Mad Money host offering a buying suggestion.

Related articles

$TJXHighAI 8/10

TJX Raises Fiscal 2027 Outlook as Q2 Results Show Broad-Based Growth

TJX raised its fiscal 2027 profit and earnings outlook after Q2 results exceeded expectations. Adjusted earnings rose 11% to $1.22 per share, and net sales increased 5% to $15.18 billion. Management also increased its long-term store target. Marmaxx, the largest division, showed the weakest growth at 1%, while other divisions performed better.

$TJXMedAI 8/10

Should Investors Buy TJX as Growth Improves but Valuation Stays Rich?

TJX reported strong Q2 results with rising sales and raised its fiscal 2027 earnings guidance to $5.15-$5.20 per share. The company plans to expand its store count to 7,500 and accelerate growth. However, its valuation remains high, with a forward P/S ratio of 2.06, above industry and historical averages. TJX's cash flow and shareholder returns are robust, but execution and cost pressures remain risks.

$TJXHighAI 8/10

TJX Falls 17.4% in the Past Month as Strong Results Meet Key Risks

TJX Companies Inc. (TJX) shares fell 17.4% in the past month despite beating Q2 earnings estimates and raising its full-year outlook. Q2 sales rose 5% to $15.18B, but Marmaxx's 1% comparable sales growth missed expectations. Management cited merchandise mix issues. TJX faces cost pressures from wages, fuel, and currency fluctuations, with Q3 gross margin expected to decline. The stock's valuation remains high, trading at a premium to its sub-industry and historical median.

$TJXMed

Tjx stock hits 52-week low at 125.5 USD

TJX Companies' stock hit a 52-week low of $125.49, down 26% from its high. Despite a 1-year decline of 9.66% and YTD losses of 17%, InvestingPro suggests it may be undervalued. Q2 fiscal 2027 results beat estimates, with $15.2B revenue and $1.22 EPS. Analysts have mixed views, with Jefferies downgrading to Hold, Bernstein maintaining Outperform, and UBS raising its target to $198.